This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
2/11/2021
Good morning and welcome to Genosha fourth quarter 2020 conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will begin the call up for your questions. Please be advised that the call is being recorded at the company's request. At this time, I'd like to turn the call over to Dan Ferry of LifeSci Advisors. Please proceed.
Thank you, Operator, and good morning, everyone. Earlier today, we issued a press release that outlines the topics we plan to discuss today. This release is available at Genosha.com under the Investors tab. During the call today, Chip Clark, President and CEO, will provide a brief corporate update, and the company's Chief Financial Officer, Diantha Duvall, will review the financial results. After the prepared remarks, we will open up the call for Q&A, and Chip, Diantha, Tom Davis, Genosha's Chief Medical Officer, and Jessica Fleckner, Genosha's Chief Scientific Officer, will then be available to answer your questions. Before we begin, I would like to remind everyone that statements made during this conference call relating to Genosha's expected future performance, future business prospects, or future events or plans may include forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from those forecasts due to the impact of many factors beyond the control of Genosha. Genosha expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Genosha's 2019 Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. It is now my pleasure to pass the call over to Chip.
Thanks, Dan, and thank you all for joining us today. We're pleased to provide updates on several important efforts. I'll start with our two clinical programs, GEN9 and GEN11. As a reminder, Gen 11 is Genosha's neoantigen-targeted peripheral T-cell therapy, or NPT therapy, which we're testing initially in checkpoint inhibitor refractory patients. Our Titan study is a Phase I-IIa study evaluating safety, biomarkers of activity, and clinical efficacy in patients with a range of tumor types across two dosing cohorts. one with a single Gen 11 dose and the other with Gen 11 administered as multiple low doses. We have initiated two clinical sites and have begun accruing patients. We'll provide updates throughout the year and expect to report initial efficacy data from a patient subset late in the fourth quarter of this year or the first quarter of 2022. Next, let me update you on GEN9, our adjuvanted peptide neoantigen vaccine. In November, we presented expanded clinical and immunogenicity findings for the ongoing Phase I-IIa trial at the 2020 Society for Immunotherapy of Cancer, or CITC, annual meeting. We were pleased to find evidence of GEN9 clinical activity on top of checkpoint inhibitor responses. Among the nine CPI-sensitive patients dosed with Gen 9, three patients experienced a novel reduction in tumor volume and achieved independent resist responses post-Gen 9 dosing, including two PRs and one CR. Five additional CPI-sensitive patients have shown disease control post-vaccination for up to 11 months. Within the CPI-resistant population, five of seven patients appear to have stabilized disease lasting up to seven months. And these results could become even more compelling with additional follow-up. Gen 9 elicited strong anti-tumor CD4 and CD8 T cell responses. We look forward to providing additional clinical and immunogenicity data from these patients in Q2. Now let me move on to some other news. A few weeks ago, we announced a milestone publication in Cancer Discovery, which shares preclinical and clinical research confirming that ATLAS is the only antigen selection platform able to identify the tumor surface-presented antigens that induce T-cell responses, whether they are neoantigens of anti-tumor T-cell responses or, uniquely to ATLAS, inhibitory antigens, which we call inhibigens, of pro-tumor CD8, and CD4 T-cell responses. We also demonstrated in the B16F10 mouse melanoma model that including an ATLAS-identified inhibigen in an otherwise protective cancer vaccine can completely abrogate such protection and showed that inhibigen-mediated suppression of anti-tumor T-cell responses cannot be overcome by checkpoint inhibitor therapy. Finally, bringing it back to Part A of the Gen 9 clinical trial, we showed that by selecting the right antigens with ATLAS, we were able to elicit T-cell responses to 99% of the vaccine antigens. Collectively, these findings further validate our unique ATLAS platform and highlight the potential importance not just of targeting the right neoantigens, but also of identifying and excluding inhibigens as cancer immunotherapy targets to maximize patient clinical efficacy benefits. As part of our efforts to investigate inhibitions further, we are excited to report a research collaboration with Dr. Ingen Strome's laboratory at the University of Minnesota, a leading group in cancer immunotherapy and T-cell engineering methods. Together, we will also develop T cell receptors targeting proprietary shared neoantigens identified via ATLAS. Now, like everyone, we've been deeply affected by the global pandemic. And we believe we may be able to help enable a next generation COVID vaccine with the potential to protect universally against SARS-CoV-2. And so we're pleased to unveil our ongoing effort to identify novel T cell antigens of the virus. As part of this effort, we have initiated a collaboration with Dr. Robert Finberg, Chair of the Department of Medicine at the University of Massachusetts, to identify conserved antigens of protective T cell responses to SARS-CoV-2. Pairing ATLAS's antigen selection capabilities with Dr. Finberg's expertise may lead to a better understanding around the role of T cells and inhibitions in the severity and duration of SARS-CoV-2 symptoms. In addition to this operational progress, we recently strengthened our executive leadership team, appointing Dr. Raymond Stapleton as Executive Vice President of Pharmaceutical Sciences and Manufacturing. Ray brings 20 plus years of industry experience leading technical quality control and manufacturing operations at commercial and clinical stage biopharmaceutical companies. I have no doubt that his leadership and expertise will prove essential to our plans to scale and commercialize our cancer immunotherapies. We are pleased at our progress on multiple fronts, not only this quarter, but throughout a very challenging 2020. We believe this momentum has set us up well for success in 2021. I'm now going to pass the call over to Diantha to summarize our financials from this quarter before opening the call up to questions. Diantha?
You're reading a preview of the GNCA Q4 2020 earnings call.
Free account.
